




RealRate

PHARMACEUTICAL 2021

IVERIC bio Inc.
Rank 191 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2021

IVERIC bio Inc.
Rank 191 of 409

The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 251% points. The greatest weakness of IVERIC bio Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is -110%, being 245% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	216,603
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,130
Liabilities, Non-Current	61
Other Assets	125
Other Compr. Net Income	3.0
Other Expenses	-3,695
Other Liabilities	0
Other Net Income	494
Property and Equipment	26
Research and Development	62,784
Revenues	0
Selling, General and Administrative Expense	25,952

Output Variable	Value in 1000 USD
Assets	216,754
Liabilities	25,191
Expenses	85,041
Stockholders Equity	191,563
Net Income	-84,547
Comprehensive Net Income	-84,546
Economic Capital Ratio	-110%

